HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kao, C.-H. Articles by Lee, J.-K. Search for Related Content PubMed PubMed Citation Articles by Kao, C.-H. Articles by Lee, J.-K.

Paclitaxel-Based Chemotherapy for Non–Small Cell Lung Cancer: Predicting the Response with ^99mTc-Tetrofosmin Chest Imaging

Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung; Department of Nuclear Medicine, Chi-Mei Foundation Hospital, Tainan; Department of Nuclear Medicine, Show-Chwan Hospital, Changhua; Department of Radiology, Jen-Ai Hospital, Taichung; Department of Nuclear Medicine, Chung-Shan Medical and Dental College, Taichung; and Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan

The purpose of this study was to retrospectively predict the chemotherapeutic response to paclitaxel for non–small cell lung cancer (NSCLC) using ^99mTc-tetrofosmin (TF) uptake and to detect the expression of 170-kDa multidrug resistance–mediated P-glycoprotein (MDR-Pgp). Methods: Before chemotherapy with paclitaxel, 20 patients with stage IIIb or IV NSCLC were enrolled in this study to undergo early and delayed ^99mTc-TF chest imaging for calculating tumor-to-normal lung ratios (T/NL) and retention indices (RI) for assessment of the MDR-Pgp in NSCLC. Results: The early and delayed mean T/NLs were 1.59 ± 0.25 and 1.50 ± 0.25, respectively, for 10 patients with a good response and 1.09 ± 0.09 and 1.03 ± 0.05, respectively, for 10 patients with a poor response. The differences were shown to be significant (P < 0.001) by independent Student t tests. However, no significant differences (P = 0.801) between good-response patients (-5.70% ± 3.67%) and poor-response patients (-5.23% ± 4.51%) were found in RI. In addition, other prognostic factors (age, sex, tumor size, stage, and cell type) were not significantly different between good-response patients and poor-response patients. Conclusion: ^99mTc-TF chest images are potential tools for understanding MDR-Pgp expression in NSCLC and for predicting the chemotherapeutic response to paclitaxel.

Key Words: ^99mTc-tetrofosmin • non–small cell lung cancer • chemotherapy • multidrug resistance–mediated P-glycoprotein

This article has been cited by other articles:

				A. Pichler, N. Zelcer, J. L. Prior, A. J. Kuil, and D. Piwnica-Worms In vivo RNA Interference-Mediated Ablation of MDR1 P-Glycoprotein Clin. Cancer Res., June 15, 2005; 11(12): 4487 - 4494. [Abstract] [Full Text] [PDF]

				O. Schillaci, A. Spanu, F. Scopinaro, F. Monteleone, M. E. Solinas, P. Volpino, P. Pirina, P. Marongiu, V. Cangemi, and G. Madeddu Mediastinal Lymph Node Involvement in Non-Small Cell Lung Cancer: Evaluation with 99mTc-Tetrofosmin SPECT and Comparison with CT J. Nucl. Med., August 1, 2003; 44(8): 1219 - 1224. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]